The optimal treatment of metastatic hormone-naive prostate cancer: Abirateron acetate or docetaxel?

Fouad Aoun; Elie El Rassy; Ghassan Sleilaty; Tarek Assi; Ziad Bakouny; Joseph Kattan

doi:10.2217/fon-2017-0445

The optimal treatment of metastatic hormone-naive prostate cancer: Abirateron acetate or docetaxel?

Fouad Aoun, Elie El Rassy, Ghassan Sleilaty, Tarek Assi, Ziad Bakouny, Joseph Kattan

Research output: Contribution to journal › Article › peer-review

7 Citations (Scopus)

Abstract

Aim: To determine whether abiraterone acetate or docetaxel should be regarded as the current standard of care for metastatic hormone-naive prostate cancer (mHNPC). Methods & materials: A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed. Results: The results of this NMA favored abiraterone acetate over docetaxel-based regimens (hazard ratio: 0.79; 95% CI: 0.64-0.99) in patients with mHNPC. The results also suggest a reconsideration of the role of prednisone in view of the absence of a survival benefit (hazard ratio: 0.98; 95% CI: 0.59-1.65) with its use. Conclusion: Despite the paucity of direct comparative evidence, the results of this NMA favor the use of abiraterone acetate in the first-line treatment of mHNPC.

Original language	English
Pages (from-to)	2785-2790
Number of pages	6
Journal	Future Oncology
Volume	13
Issue number	30
DOIs	https://doi.org/10.2217/fon-2017-0445
Publication status	Published - 1 Dec 2017
Externally published	Yes

Keywords

Abiraterone acetate
Docetaxel
First line
Hormone-naive prostate cancer
Network meta-analysis

Access to Document

10.2217/fon-2017-0445

Cite this

@article{3335e2d416424214952ae82848029617,

title = "The optimal treatment of metastatic hormone-naive prostate cancer: Abirateron acetate or docetaxel?",

abstract = "Aim: To determine whether abiraterone acetate or docetaxel should be regarded as the current standard of care for metastatic hormone-naive prostate cancer (mHNPC). Methods & materials: A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed. Results: The results of this NMA favored abiraterone acetate over docetaxel-based regimens (hazard ratio: 0.79; 95% CI: 0.64-0.99) in patients with mHNPC. The results also suggest a reconsideration of the role of prednisone in view of the absence of a survival benefit (hazard ratio: 0.98; 95% CI: 0.59-1.65) with its use. Conclusion: Despite the paucity of direct comparative evidence, the results of this NMA favor the use of abiraterone acetate in the first-line treatment of mHNPC.",

keywords = "Abiraterone acetate, Docetaxel, First line, Hormone-naive prostate cancer, Network meta-analysis",

author = "Fouad Aoun and Rassy, {Elie El} and Ghassan Sleilaty and Tarek Assi and Ziad Bakouny and Joseph Kattan",

note = "Publisher Copyright: {\textcopyright} 2017 Future Medicine Ltd.",

year = "2017",

month = dec,

day = "1",

doi = "10.2217/fon-2017-0445",

language = "English",

volume = "13",

pages = "2785--2790",

journal = "Future Oncology",

issn = "1479-6694",

number = "30",

}

TY - JOUR

T1 - The optimal treatment of metastatic hormone-naive prostate cancer

T2 - Abirateron acetate or docetaxel?

AU - Aoun, Fouad

AU - Rassy, Elie El

AU - Sleilaty, Ghassan

AU - Assi, Tarek

AU - Bakouny, Ziad

AU - Kattan, Joseph

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Aim: To determine whether abiraterone acetate or docetaxel should be regarded as the current standard of care for metastatic hormone-naive prostate cancer (mHNPC). Methods & materials: A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed. Results: The results of this NMA favored abiraterone acetate over docetaxel-based regimens (hazard ratio: 0.79; 95% CI: 0.64-0.99) in patients with mHNPC. The results also suggest a reconsideration of the role of prednisone in view of the absence of a survival benefit (hazard ratio: 0.98; 95% CI: 0.59-1.65) with its use. Conclusion: Despite the paucity of direct comparative evidence, the results of this NMA favor the use of abiraterone acetate in the first-line treatment of mHNPC.

AB - Aim: To determine whether abiraterone acetate or docetaxel should be regarded as the current standard of care for metastatic hormone-naive prostate cancer (mHNPC). Methods & materials: A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed. Results: The results of this NMA favored abiraterone acetate over docetaxel-based regimens (hazard ratio: 0.79; 95% CI: 0.64-0.99) in patients with mHNPC. The results also suggest a reconsideration of the role of prednisone in view of the absence of a survival benefit (hazard ratio: 0.98; 95% CI: 0.59-1.65) with its use. Conclusion: Despite the paucity of direct comparative evidence, the results of this NMA favor the use of abiraterone acetate in the first-line treatment of mHNPC.

KW - Abiraterone acetate

KW - Docetaxel

KW - First line

KW - Hormone-naive prostate cancer

KW - Network meta-analysis

UR - http://www.scopus.com/inward/record.url?scp=85045000922&partnerID=8YFLogxK

U2 - 10.2217/fon-2017-0445

DO - 10.2217/fon-2017-0445

M3 - Article

C2 - 29188727

AN - SCOPUS:85045000922

SN - 1479-6694

VL - 13

SP - 2785

EP - 2790

JO - Future Oncology

JF - Future Oncology

IS - 30

ER -

The optimal treatment of metastatic hormone-naive prostate cancer: Abirateron acetate or docetaxel?

Abstract

Keywords

Access to Document

Other files and links

Cite this